Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt

The key Key Bunion Companies in the market include – Heron Therapeutics, Lotus Clinical Research, LLC, Cali Pharmaceuticals LLC, Grünenthal GmbH, Heron Therapeutics, Pacira Pharmaceuticals, Inc, Mallinckrodt, Cali Pharmaceuticals LLC, Johnson & Johnson Pharma, Pfizer, Javelin Pharmaceuticals, Baudax Bio, Xanodyne Pharmaceuticals, and others .

DelveInsight’s “Bunion Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast

 

Some of the key facts of the Bunion Market Report: 

  • The Bunion market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In August 2024, PainReform announced that it has successfully identified the most effective delivery method for PRF-110 in bunionectomy procedures. This achievement positions PRF-110 as a leading option for managing post-surgical pain.

  • DelveInsight’s estimates indicate that the largest market size for hallux valgus was in the United States, amounting to approximately USD 3 billion in 2023.

  • In 2023, conservative treatment accounted for the second-largest revenue share at approximately 40%, while bunionectomy dominated the market with around 60% share across the 7MM.

  • Among the EU4 and the UK, Germany reported the highest revenue, approximately USD 700 million, in 2023.

  • In 2023, the United States had approximately 60 million diagnosed prevalent cases of hallux valgus.

  • In 2023, the total number of gender-specific prevalent cases of hallux valgus in the 7MM was approximately 45 million for males and around 105 million for females.

  • Among the EU4 and the UK, Germany reported the highest number of hallux valgus cases, with approximately 20 million cases in 2023.

  • In 2023, the number of treated cases of hallux valgus in the United States was approximately 4 million, and this figure is expected to increase during the forecast period.

  • Key Bunion Companies: Heron Therapeutics, Lotus Clinical Research, LLC, Cali Pharmaceuticals LLC, Grünenthal GmbH, Heron Therapeutics, Pacira Pharmaceuticals, Inc, Mallinckrodt, Cali Pharmaceuticals LLC, Johnson & Johnson Pharma, Pfizer, Javelin Pharmaceuticals, Baudax Bio, Xanodyne Pharmaceuticals, and others

  • Key Bunion Therapies: HTX-034, Ropivacaine, Naropin, Tapentadol, HTX-011A, Liposome bupivacaine, SKY0402, COV155, Analgesic Non Narcotic, Tapentadol (CG5503), valdecoxib, Intranasal Morphine (MNS075), Exparel, N1539, diclofenac potassium (XP21L), and others

  • The Bunion epidemiology based on gender analyzed that women are more frequently diagnosed with Hallux Valgus compared to men.

  • The Bunion market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bunion pipeline products will significantly revolutionize the Bunion market dynamics.

 

Bunion Overview

A bunion is a bony bump that forms at the base of the big toe, where it attaches to the foot. This condition occurs when the big toe pushes against the adjacent toe, causing the joint to stick out and become misaligned. Bunions can lead to pain, swelling, and stiffness in the affected area, making it difficult to wear shoes or walk comfortably. They are often associated with factors such as genetics, improper footwear, and certain medical conditions. Treatment options range from conservative measures, like changing footwear and using orthotics, to surgical procedures for severe cases.

 

Get a Free sample for the Bunion Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/bunion-market

 

Bunion Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Bunion Epidemiology Segmentation:

The Bunion market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Bunion

  • Prevalent Cases of Bunion by severity

  • Gender-specific Prevalence of Bunion

  • Diagnosed Cases of Episodic and Chronic Bunion

 

Download the report to understand which factors are driving Bunion epidemiology trends @ Bunion Epidemiology Forecast

 

Bunion Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bunion market or expected to get launched during the study period. The analysis covers Bunion market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bunion Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Bunion Therapies and Key Companies

  • HTX-034: Heron Therapeutics

  • Ropivacaine: Lotus Clinical Research, LLC

  • Naropin: Cali Pharmaceuticals LLC

  • Tapentadol: Grünenthal GmbH

  • HTX-011A: Heron Therapeutics

  • Liposome bupivacaine: Pacira Pharmaceuticals, Inc

  • SKY0402: Pacira Pharmaceuticals, Inc

  • COV155: Mallinckrodt

  • Analgesic Non Narcotic: Cali Pharmaceuticals LLC

  • Tapentadol (CG5503): Johnson & Johnson Pharma

  • valdecoxib: Pfizer

  • Intranasal Morphine (MNS075): Javelin Pharmaceuticals

  • Exparel: Pacira Pharmaceuticals, Inc

  • N1539: Baudax Bio

  • diclofenac potassium (XP21L): Xanodyne Pharmaceuticals

 

Discover more about therapies set to grab major Bunion market share @ Bunion Treatment Landscape

 

Scope of the Bunion Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Bunion Companies: Heron Therapeutics, Lotus Clinical Research, LLC, Cali Pharmaceuticals LLC, Grünenthal GmbH, Heron Therapeutics, Pacira Pharmaceuticals, Inc, Mallinckrodt, Cali Pharmaceuticals LLC, Johnson & Johnson Pharma, Pfizer, Javelin Pharmaceuticals, Baudax Bio, Xanodyne Pharmaceuticals, and others

  • Key Bunion Therapies: HTX-034, Ropivacaine, Naropin, Tapentadol, HTX-011A, Liposome bupivacaine, SKY0402, COV155, Analgesic Non Narcotic, Tapentadol (CG5503), valdecoxib, Intranasal Morphine (MNS075), Exparel, N1539, diclofenac potassium (XP21L), and others

  • Bunion Therapeutic Assessment: Bunion current marketed and Bunion emerging therapies

  • Bunion Market Dynamics: Bunion market drivers and Bunion market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Bunion Unmet Needs, KOL’s views, Analyst’s views, Bunion Market Access and Reimbursement 

 

To know more about Bunion companies working in the treatment market, visit @ Bunion Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Bunion Market Report Introduction

2. Executive Summary for Bunion

3. SWOT analysis of Bunion

4. Bunion Patient Share (%) Overview at a Glance

5. Bunion Market Overview at a Glance

6. Bunion Disease Background and Overview

7. Bunion Epidemiology and Patient Population

8. Country-Specific Patient Population of Bunion 

9. Bunion Current Treatment and Medical Practices

10. Bunion Unmet Needs

11. Bunion Emerging Therapies

12. Bunion Market Outlook

13. Country-Wise Bunion Market Analysis (2020–2034)

14. Bunion Market Access and Reimbursement of Therapies

15. Bunion Market Drivers

16. Bunion Market Barriers

17.  Bunion Appendix

18. Bunion Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt